The U.S. Food and ‌Drug Administration said on Friday it has approved a wearable form of Sanofi's blood cancer drug, Sarclisa, offering multiple myeloma patients a less burdensome alternative to intravenous ‌infusions.

The drug can now be ​given under the skin through a wearable injector.

The FDA's approval gives the ⁠French drugmaker a regulatory win as new CEO ​Belén Garijo seeks to strengthen its pipeline ⁠and reduce investor concerns about reliance on asthma drug Dupixent, its biggest-selling medicine.

Sanofi, last month, named Paulo Fontoura as ‌its new R&D head.

The new form ​of the drug, ‌called Sarclisa Escena, is delivered through an on-body injector, a ‌wearable device attached to the skin, and is approved for patients with multiple myeloma — a rare ⁠blood cancer that ‌begins in the ⁠bone marrow when plasma cells become cancerous and multiply ⁠uncontrollably.

Subcutaneous ⁠dosing can significantly reduce time spent in infusion centers for patients ‌who receive repeated treatment courses, while also easing the strain on oncology clinics and nurses.

An intravenous form ‌of ​the drug first ‌won FDA approval in 2020 for previously treated patients with relapsed multiple myeloma.